Gil Leibowitz
Israel
Research Article
Saxagliptin Responder Analysis: A Pooled Analysis of 5 Clinical Trials
Author(s): Mikaela Sjostrand, Gil Leibowitz, Nayyar Iqbal, William Cook, Cheryl Wei and Boaz HirshbergMikaela Sjostrand, Gil Leibowitz, Nayyar Iqbal, William Cook, Cheryl Wei and Boaz Hirshberg
Objective: To assess the treatment response of patients with T2DM to saxagliptin at 24 weeks based on their initial response to saxagliptin at 12 weeks. Methods: Data were pooled from five 24-week, randomized, placebo-controlled trials of saxagliptin. Patients (N=1994) were categorized by change in glycated hemoglobin (HbA1c) after 12 weeks of saxagliptin treatment as responders (HbA1c decrease ≥ 0.5%; 61% of saxagliptin-treated patients), intermediate responders (HbA1c decrease ≥ 0.2% and <0.5%; 14% of patients), and nonresponders (HbA1c decrease <0.2%; 25% of patients). Results: The adjusted mean change [95% CI] from baseline to week 24 in HbA1c with saxagliptin was greatest in responders (–1.05% [–1.11%, – 0.99%]) followed by intermediate responders (–0.32% [–0.43%, –0.22%]) and nonresponders (0.27% [.. View More»
